Free Deal Calculator

Calculate Cell Therapy Deal Values in Minutes

Get precise licensing valuations for TIL, NK cells, and non-CAR-T therapies using real market data

Market-Validated Pricing

Access real deal data from $700M-$2.5B transactions. Our algorithm factors in the 15% premium cell therapies command over baseline biotech valuations.

Instant Professional Reports

Generate comprehensive valuation reports in under 5 minutes. Perfect for board presentations, investor meetings, and partnership negotiations.

TIL & NK Cell Expertise

Purpose-built for non-CAR-T cellular therapies including tumor-infiltrating lymphocytes and natural killer cells with specialized market benchmarks.

$60M-$250M

Phase 2 Upfront Range

200+

Cell Therapy Deals Analyzed

15%

Average Premium vs Baseline

$2.5B

Max Deal Values Tracked

How It Works

Input Your Asset Details

Enter your cell therapy type, development stage, indication, and key clinical data points

AI Analyzes Market Data

Our algorithm compares against 200+ comparable deals and applies cell therapy-specific valuation models

Get Your Valuation Report

Receive detailed upfront, milestone, and total deal value ranges with supporting market rationale

Frequently Asked Questions

How accurate are cell therapy valuations compared to other modalities?

Cell therapies typically command a 15% premium over baseline biotech valuations due to manufacturing complexity and specialized expertise required. Our calculator incorporates this premium plus therapy-specific risk factors.

What's included in typical TIL and NK cell licensing deals?

Standard deals include $60M-$250M upfront for Phase 2 assets, development milestones up to $500M, commercial milestones up to $1B+, plus tiered royalties of 8-15% depending on indication and territory.

How do manufacturing costs affect cell therapy deal structures?

Manufacturing represents 30-50% of COGS for cell therapies vs 5-10% for traditional drugs. This drives higher milestone payments tied to manufacturing scale-up and CMC achievements in licensing agreements.

Which indications command the highest premiums for non-CAR-T therapies?

Solid tumor applications for TIL therapy and hematological cancers for NK cells typically see 20-30% higher valuations due to large addressable markets and differentiated mechanisms of action.

Ready to Calculate Your Deal Terms?

Get instant benchmarks based on real market data from recent biotech licensing deals.

Start Calculating